現在地

松阪 諭(マツサカ サトシ; Matsusaka, Satoshi)

研究者情報全体を表示

その他の論文・記事
  • RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy
    H Osumi; E Shinozaki; M Suenaga; S Matsusaka; T Konishi; ...
    Int J Cancer/139(4)/pp.803-811, 2016
  • Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012
    MD Berger; D Yang; Y Sunakawa; W Zhang; Y Ning; S Matsusa...
    Oncotarget/7(33)/pp.53668-53678, 2016
  • Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
    S Okazaki; F Loupakis; S Stintzing; S Cao; W Zhang; D Yan...
    Mol Cancer Ther/15(7)/pp.1740-1745, 2016
  • Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
    M Suenaga; T Mashima; N Kawata; T Wakatsuki; Y Horiike; S...
    Oncotarget/7(23)/pp.34811-34823, 2016
  • Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
    H Osumi; E Shinozaki; M Osako; Y Kawazoe; M Oba; T Misaka...
    Mol Clin Oncol./3(5)/pp.1053-1057, 2015
  • Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab.
    H Osumi; S Matsusaka; M Suenaga; E Shinozaki; N Mizunuma
    Onco Targets Ther./8/pp.2005-2013, 2015
  • Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
    Y Ning; DL Hanna; W Zhang; A Mendez; D Yang; R El-Khoueir...
    Mol Cancer Ther/14(10)/pp.2401-2408, 2015
  • Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerlin...
    Mol Cancer Ther/14(10)/pp.2374-2381, 2015
  • Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    M Suenaga; N Mizunuma; S Matsusaka; E Shinozaki; M Ozaka;...
    Drug Des Devel Ther/9/pp.3099-3108, 2015
  • Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
    M Suenaga; Fujimoto Y; S Matsusaka; E Shinozaki; T Akiyos...
    Onco Targets Ther/8/pp.1111-1118, 2015
  • Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.
    Stremitzer S; W Zhang; Yang D; Y Ning; S Stintzing; Y Sun...
    Ann Oncol./26(8)/pp.1728-1733, 2015
  • A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction
    S Suzuki; S Matsusaka; M Hirai; H Shibata; K Takagi; N Mi...
    Int J Oncol/47(1)/pp.97-105, 2015
  • Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J
    S Stremitzer; Y Sunakawa; W Zhang; D Yang; Y Ning; S Stin...
    Pharmacogenomics J/15(6)/pp.521-529, 2015
  • Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
    S Stremitzer; W Zhang; D Yang; Y Ning; S Stintzing; A Seb...
    Cancer/121(11)/pp.1898-1905, 2015
  • Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab.
    M Suenaga; N Mizunuma; E Shinozaki; S Matsusaka; M Ozaka;...
    Onco Targets Ther/8/pp.243-249, 2015
  • A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
    Ishihara S; S Matsusaka; K Kondo; H Horie; Uehara K; M Og...
    Radiat Oncol/10/pp.24-24, 2015
  • Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.
    Y Sunakawa; S Stremitzer; S Cao; W Zhang; D Yang; T Wakat...
    Ann Oncol./26(2)/pp.332-339, 2015
  • Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer
    Sebio A; A Gerger; S Matsusaka; D Yang; W Zhang; S Stremi...
    Pharmacogenet Genomics./25(1)/pp.30-37, 2015
  • A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial)
    Matsusaka Satoshi; Ishihara S; K Kondo; H Horie; K Uehara...
    Radiother Oncol/116(2)/pp.209-213, 2015
  • Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
    H Osumi; E Shinozaki; M Suenaga; Y Kumekawa; M Ogura; M O...
    BMC Cancer/15/pp.760-760, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Y Sunakawa; S Stintzing; S Cao; V Heinemann; C Cremolini;...
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Matsusaka Satoshi
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.
    Y Sato; S Matsusaka; M Suenaga; E Shinozaki; N. Mizunuma
    Onco Targets Ther./8/pp.3329-3336, 2015
  • Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients.
    Matsusaka Satoshi; S Matsusaka; T Wakatsuki; M Suenaga; E...
    Mol Clin Oncol./3(6)/pp.1295-1300, 2015
  • Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.
    T Wakatsuki; S Stintzing; W Zhang; D Yang; M Azuma; Y Nin...
    Pharmacogenet Genomics/24(11)/pp.539-547, 2014